Cloud Banner

Pharmaceutical

Image

Global Bulbospinal Muscular Atrophy Drugs Market – Industry Trends and Forecast to 2030

  • Pharmaceutical
  • Upcoming Report
  • Oct 2023
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global Bulbospinal Muscular Atrophy Drugs Market – Industry Trends and Forecast to 2030

Market Size in USD Billion

CAGR - 12.67% Diagram

Diagram Forecast Period 2022–2030
Diagram Market Size (Base Year) USD 690.60 Million
Diagram Market Size (Forecast Year) USD 1793.48 Million
Diagram CAGR 12.67%

Global Bulbospinal Muscular Atrophy Drugs Market, By Drug Class (5α-Reductase Inhibitors (5-ARIs), Gonadotropin-releasing Hormone (GnRH) Agonists and Others), Drugs (Leuprorelin, Dutasteride and Others), Route of Administration (Oral and Parenteral), Distribution Channel (Hospital Pharmacy, Retail Pharmacy and Online Pharmacy), End-Users (Hospitals, Homecare, Specialty Clinics and Others) - Industry Trends and Forecast to 2030.

Bulbospinal Muscular Atrophy Drugs Market

Bulbospinal Muscular Atrophy Drugs Market Analysis and Size

Bulbospinal muscular atrophy (Kennedy’s disease) is a disease under which bulblike structure forms in the lower part of the brain that contains nerve cells controlling muscles in the face, mouth and throat. The condition occurs due to loss of nerve cells in the brain stem and spinal cord, this result in stoppage of messages from brain to muscles for movement. The patients suffering with this disease have difficulty in speaking, standing, walking and controlling their head movements. In worse condition patients can have trouble swallowing and breathing. This disorder mainly affects men and does not occur in females, who are protected by their low levels of testosterone in the body, accounting for the sex-limited inheritance pattern of this disorder.

Data Bridge Market Research analyses that the bulbospinal muscular atrophy drugs market which was USD 690.60 million in 2022, would reach up to USD 1,793.48 million by 2030, and is expected to undergo a CAGR of 12.67% during the forecast period. “Hospitals” dominates the end-user segment of the bulbospinal muscular atrophy drugs market owing to presence of higher number of hospitalized patients. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Bulbospinal Muscular Atrophy Drugs Market Scope and Segmentation

Report Metric

Details

Forecast Period

2023 to 2030

Base Year

2022

Historic Years

2021 (Customizable to 2015-2020)

Quantitative Units

Revenue in USD Million, Volumes in Units, Pricing in USD

Segments Covered

Drug Class (5α-Reductase Inhibitors (5-ARIs), Gonadotropin-releasing Hormone (GnRH) Agonists and Others), Drugs (Leuprorelin, Dutasteride and Others), Route of Administration (Oral and Parenteral), Distribution Channel (Hospital Pharmacy, Retail Pharmacy and Online Pharmacy), End-Users (Hospitals, Homecare, Specialty Clinics and Others)

Countries Covered

U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

Market Players Covered

Novartis AG (Switzerland), F. Hoffmann-La Roche Ltd (Switzerland), Boehringer Ingelheim International GmbH (Germany), Pfizer Inc. (U.S.), Ionis Pharmaceuticals, Inc. (U.S.), CYTOKINETICS, INC. (U.S.), Regeneron Pharmaceuticals, Inc. (U.S.), Salarius Pharmaceuticals, Inc. (U.S.), Leadiant Biosciences, Inc. (Italy), Abbott (U.S.), Novo Nordisk A/S (Denmark), Takeda Pharmaceutical Company Limited (Japan), AstraZeneca (U.K.), Catalyst Pharma (U.S.), PTC Therapeutics (U.S.) and Natera (U.S.)

Market Opportunities

  • Development of targeted therapies
  • Increased patient awareness and diagnosis
  • Orphan drug incentives

Market Definition

Bulbospinal muscular atrophy (BSMA), also known as Kennedy's disease, is a rare genetic disorder characterized by the progressive degeneration of motor neurons in the spinal cord and brainstem. It primarily affects males and is caused by a mutation in the androgen receptor gene. BSMA leads to muscle weakness, atrophy, and a range of symptoms such as difficulty in speaking, swallowing, and breathing, and muscle cramps and twitching. Symptoms typically appear in adulthood, and the condition worsens over time. While there is currently no cure for BSMA, various treatments and therapies aim to manage its symptoms and improve the quality of life for affected individuals. Some of the therapeutic approaches include androgen deprivation therapy, physical and occupational therapy among others.

Global Bulbospinal Muscular Atrophy Drugs Market Dynamics

Drivers

  • Increasing Prevalence and Diagnosis Rate

Advances in medical knowledge and genetic testing technologies have resulted in more accurate and timely diagnoses of rare diseases such as BSMA. As awareness among healthcare professionals and the public grows, the number of diagnosed cases is expected to increase. The expanding pool of identified BSMA patients creates a larger market for pharmaceutical companies developing drugs for the condition.

  • Advancements in Genetic Research

Ongoing genetic research has deepened our understanding of the molecular mechanisms underlying BSMA. This knowledge is essential for the development of targeted therapies that address the genetic mutations responsible for the disease. As genetic research continues to uncover the intricacies of BSMA, it provides opportunities for the development of more effective and specific drugs.

Opportunities

  • Development of Targeted Therapies

As research into the underlying genetic mechanisms of BSMA advances, there is potential for the development of more targeted and effective therapies. This could lead to the introduction of novel drugs that specifically address the genetic mutations responsible for BSMA, providing patients with more tailored treatment options.

  • Increased Patient Awareness and Diagnosis

As awareness about BSMA grows among healthcare professionals and the public, more patients may be accurately diagnosed. This increased diagnosis rate can lead to a larger patient pool seeking treatment, thus expanding the market for BSMA drugs.

  • Orphan Drug Incentives

BSMA is considered a rare disease, making it eligible for orphan drug status in many regions. This designation can provide drug developers with financial incentives, tax benefits, and market exclusivity, encouraging investment in BSMA drug research and development.

Restraints/Challenges

  • Clinical Trial Challenges

Conducting clinical trials for rare diseases can be challenging due to the limited number of eligible participants. Recruitment and retention of patients for trials may be difficult, potentially delaying drug development timelines.

  • High Development Costs

Developing drugs for rare diseases can be cost-intensive, and the potential return on investment may be uncertain due to the limited market size. This financial risk can deter some pharmaceutical companies from pursuing BSMA drug development

This bulbospinal muscular atrophy drugs market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the bulbospinal muscular atrophy drugs market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Bulbospinal Muscular Atrophy Drugs Market Scope

The bulbospinal muscular atrophy drugs market is segmented on the basis of drug class, drugs, route of administration, distribution channel and end-users. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Drug Class

  • 5α-Reductase Inhibitors (5-ARIs)
  • Gonadotropin-releasing Hormone (GnRH) Agonists
  • Others

Drugs

  • Leuprorelin
  • Dutasteride
  • Others

Route of Administration

  • Oral
  • Parenteral

Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

End-Users

  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others

Bulbospinal Muscular Atrophy Drugs Market Regional Analysis/Insights

The bulbospinal muscular atrophy drugs market is analysed and market size insights and trends are provided by drug class, drugs, route of administration, distribution channel and end-users as referenced above.

The countries covered in the bulbospinal muscular atrophy drugs market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America leads the bulbospinal muscular atrophy drugs market due to the increase in the prevalence of bulbospinal muscular atrophy and the unhealthy lifestyle.

Asia-Pacific region is expected to expand at a significant growth rate in the forecast period because of the rise in the population and increase in the healthcare awareness and the high adoption of healthcare solutions.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and up-stream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Bulbospinal Muscular Atrophy Drugs Market Share Analysis

The bulbospinal muscular atrophy drugs market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the company’s focus related to bulbospinal muscular atrophy drugs market.

Some of the major players operating in the bulbospinal muscular atrophy drugs market are:

  • Novartis AG (Switzerland)
  • F. Hoffmann-La Roche Ltd (Switzerland)
  • Boehringer Ingelheim International GmbH (Germany)
  • Pfizer Inc. (U.S.)
  • Ionis Pharmaceuticals, Inc. (U.S.)
  • CYTOKINETICS, INC. (U.S.)
  • Regeneron Pharmaceuticals, Inc. (U.S.)
  • Salarius Pharmaceuticals, Inc. (U.S.)
  • Leadiant Biosciences, Inc. (Italy)
  • Abbott (U.S.)
  • Novo Nordisk A/S (Denmark)
  • Takeda Pharmaceutical Company Limited (Japan)
  • AstraZeneca (U.K.)
  • Catalyst Pharma (U.S.)
  • PTC Therapeutics (U.S.)
  • Natera (U.S.)


SKU-

Please fill in the below form for detailed Table of Content

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Table

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Figure

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for Infographics

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Research Methodology:

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Please fill in the below form for Research Methodology

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Customization Available:

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Please fill in the below form for Available Customization

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

FREQUENTLY ASK QUESTIONS

The Bulbospinal Muscular Atrophy Drugs Market will be worth USD 1,793.48 million by 2030.
The Bulbospinal Muscular Atrophy Drugs Market growth rate is 12.67% during the forecast period.
Increasing Prevalence and Diagnosis Rate & Advancements in Genetic Research are the growth drivers of the Bulbospinal Muscular Atrophy Drugs Market.
The drug class, drugs, route of administration, distribution channel and end-users are the factors on which the Bulbospinal Muscular Atrophy Drugs Market research is based.
Novartis AG (Switzerland), F. Hoffmann-La Roche Ltd (Switzerland), Boehringer Ingelheim International GmbH (Germany), Pfizer Inc. (U.S.), Ionis Pharmaceuticals, Inc. (U.S.), CYTOKINETICS, INC. (U.S.), Regeneron Pharmaceuticals, Inc. (U.S.), Salarius Pharmaceuticals, Inc. (U.S.) are the major companies in the Bulbospinal Muscular Atrophy Drugs Market.
Free Sample Report

CHOOSE LICENCE TYPE

  • 7000.00
  • 4800.00
  • 3000.00
  • 8000.00
  • 12000.00

Why Choose Us

Industry Coverage

DBMR works across the globe in multiple industries which equip us with knowledge across verticals and provide our clients with insights not only from their industry but how other industries will impact their ecosystem.

Regional Coverage

Coverage of Data Bridge is not restricted to developed or emerging economies. We work across the globe covering the largest array of countries where no other market research or business consulting firm has ever conducted research; creating growth opportunities for our clients in areas which are still unknown.

Technology Coverage

In today’s world, technology drives the market sentiment, so our vision is to provide our clients insights not only for developed technologies but upcoming and disrupting technological changes throughout the product lifecycle by enabling them with unforeseen opportunities in the market which will create disruption in their industry. This leads to innovation and our clients to come out as winners.

Goal Oriented Solutions

DBMR goal is to help our clients achieve their goals through our solutions; hence we formatively create the most appropriate solutions for our client needs, saving time and efforts for them to drive their grand strategies.

Unparallel Analyst Support

Our analysts take pride in our clients’ success. Unlike others, we believe in working along our clients to achieve their goals with 24 hours analyst support determining the correct needs and inspire innovation through service.

Banner

Client Testimonials